Bristol-myers Squibb Compnay

Viiv Healthcare UK (no. 4) Limited

Eisai R&d Management Co., Ltd.

Chung-Pin H Chen

Yasutsugu Ueda

Timothy P Connolly

David Kenneth Leahy

Nicholas A Meanwell

John F Kadow

Tao Wang

Zhongxing Zhang

Kap-Sun Yeung

Nachimuthu Soundararajan

Shawn K Pack

Pierre Sirard

Kathia Levesque

Dominique Thoraval

Yadagiri R Pendri

John K Thottathil

Richard P Polniaszek

John D Matiskella

Qi Gao

Milan N Stojanovic

Shaopeng Wang

Jing Liang

Dhileepkumar Krishnamurty

Ramesh N Patel

David R Kronenthal

Richard H Mueller

Thomas W Hudyma

Joseph F Payack

David J Kucera

Chong-Hui Gu

Purushotham Vemishetti

Amit Banerjee

Jonathan Clive Tripp

Jeffrey M Evans

Jerzy Golik

Richard J Fox

Wendel William Doubleday

Mitchell J Schultz

Zhongping Shi

Dayne Dustan Fanfair

Ambarish K Singh

Jeffrey T Bien

Maotang X Zhou

Gerald L Powers

Sunil S Patel

Siva Josyula Prasad

Srividya Ramakrishnan

Michael G Fakes

Anne I Song

Sushil K Rijhwani

Jaquan Kalani Levons

Laxma Reddy Kolla

Bing-Shiou Yang

Yeung Yu Chan

Dawn DiGiugno Parker

Dejah T Petsch

Charles Lewis

Venkatramana M Rao

Sabrina E Ivy

Saravanababu Murugesan

Susanne Kiau

Milan Stojanovic

Joseph Francis Payack

Yeung Y Chan

Blisse Vakkalagadda

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:

Salts of prodrugs of piperazine and substituted piperidine antiviral agents

This invention provides for prodrug Compounds I, pharmaceutical compositions thereof, and their use in treating HIV infection. wherein:X is C or N with the proviso that when X is N, Rdoes not exist;W is C or N with the proviso that when W is N, Rdoes not exist;V is C;E is hydrogen or a pharmaceutically acceptable salt thereof; andY is selected from the group consisting of  Also, this invention provides for intermediate Compounds II useful in making prodrug Compounds I. wherein:L and M are independently selected from the group consisting of C-Calkyl, phenyl, benzyl, trialkylsilyl, -2,2,2-trichloroethoxy and 2-trimethylsilylethoxy.

A method for making the compound of Formula I: is set forth using alkylation, amidation, chlorination and phosphate installation procedures.

Methods of making HIV attachment inhibitor prodrug compound and intermediates

Prodrugs of piperazine and substituted piperidine antiviral agents

Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-yl)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine its salts and solvates thereof are herein set forth, as are pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).

[object Object]

The instant disclosure provides crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-c]pyridin-3-yl]-1,2-dioxoethyl]-piperazine, salts and solvates thereof. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form(s), as well of methods of using the crystalline form(s) in the treatment of HIV and/or AIDS, and methods for obtaining such crystalline form(s).

Intermediates useful in the preparation of the antiviral agent entecavir are disclosed. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various processes useful in the preparation of entecavir are also disclosed.

Intermediates in the preparation of the antiviral agent [1S-(1&#x3b1;, 3&#x3b1;, 4&#x3b2;)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxmethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Processes are disclosed for preparing the antiviral agent entecavir. A resin adsorption process for the isolation and purification of entecavir is also disclosed. Various intermediates useful in the preparation of entecavir are also disclosed.

Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta )]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one

Process for water soluble azole compounds

Water soluble prodrugs of azole compounds

Growing community of inventors

Madison, CT, United States of America

Chung-Pin H Chen